Pathogenesis of cancer cachexia
- PMID: 15334872
Pathogenesis of cancer cachexia
Abstract
Cachexia is a progressive wasting syndrome characterized by extensive loss of adipose tissue and skeletal muscle. It occurs in about half of all cancer patients. While anorexia also may be present, the energy deficit alone does not explain the pathogenesis of cachexia. The presence of an acute phase response (APR) has been linked to accelerated weight loss and a shortened survival time. The APR is thought to be initiated by cytokines such as interleukin (IL)-6 and IL-8, production of which is induced by a tumor factor, proteolysis inducing factor (PIF). Cachectic cancer patients also show an increased expression of uncoupling protein-3 in muscle, which may act as an energy sink, increasing energy expenditure. Loss of adipose tissue appears to be due to an increase in degradation of triglycerides, rather than a decrease in synthesis. One candidate for this effect is a tumor lipid mobilizing factor, which stimulates lipolysis directly through a cyclic AMP-mediated process via interaction with a beta3-adrenergic receptor. Loss of skeletal muscle arises from both a depression in protein synthesis and an increase in protein degradation. The major proteolytic pathway involved in intracellular protein breakdown in cachectic muscle is the ATP-ubiquitin-dependent proteolytic pathway. Both PIF and tumor necrosis factor-alpha, but not other cytokines, can induce expression of the key regulatory components of this pathway. Eicosapentaenoic acid, found in oily fish, effectively attenuates protein degradation in cachectic muscle by inhibiting the increased proteasome expression and can stabilize body weight in cachectic cancer patients.
Similar articles
-
Tumor-host interactions.J Cell Biochem. 2004 Nov 15;93(5):871-7. doi: 10.1002/jcb.20246. J Cell Biochem. 2004. PMID: 15449322 Review.
-
Mechanisms of cancer cachexia.Physiol Rev. 2009 Apr;89(2):381-410. doi: 10.1152/physrev.00016.2008. Physiol Rev. 2009. PMID: 19342610 Review.
-
The 'cancer cachectic factor'.Support Care Cancer. 2003 Feb;11(2):73-8. doi: 10.1007/s00520-002-0408-6. Epub 2002 Nov 5. Support Care Cancer. 2003. PMID: 12560934
-
Cancer cachexia.Langenbecks Arch Surg. 2004 Aug;389(4):299-305. doi: 10.1007/s00423-004-0486-7. Epub 2004 May 28. Langenbecks Arch Surg. 2004. PMID: 15168125 Review.
-
Waste management - cytokines, growth factors and cachexia.Cytokine Growth Factor Rev. 2006 Dec;17(6):475-86. doi: 10.1016/j.cytogfr.2006.09.006. Epub 2006 Nov 22. Cytokine Growth Factor Rev. 2006. PMID: 17118696 Review.
Cited by
-
The effect of exercise on IL-6-induced cachexia in the Apc ( Min/+) mouse.J Cachexia Sarcopenia Muscle. 2012 Jun;3(2):117-37. doi: 10.1007/s13539-011-0047-1. Epub 2011 Nov 30. J Cachexia Sarcopenia Muscle. 2012. PMID: 22476915 Free PMC article.
-
Tumor macroenvironment and metabolism.Semin Oncol. 2014 Apr;41(2):281-95. doi: 10.1053/j.seminoncol.2014.02.005. Epub 2014 Mar 1. Semin Oncol. 2014. PMID: 24787299 Free PMC article. Review.
-
Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals.J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):577-586. doi: 10.1002/jcsm.12100. Epub 2016 Feb 24. J Cachexia Sarcopenia Muscle. 2016. PMID: 27030817 Free PMC article.
-
Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer.PLoS One. 2014 Jul 10;9(7):e102436. doi: 10.1371/journal.pone.0102436. eCollection 2014. PLoS One. 2014. PMID: 25010770 Free PMC article.
-
Cancer Cachexia and MicroRNAs.Mediators Inflamm. 2015;2015:367561. doi: 10.1155/2015/367561. Epub 2015 Oct 4. Mediators Inflamm. 2015. PMID: 26504359 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous